Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
WARREN, N.J., Feb. 07, 2017 -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for Tadalafil Oral Soluble Film (Tadalafil OSF) for the treatment of erectile dysfunction. The Tadalafil OSF NDA has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 18, 2017.
“The acceptance of the NDA and assignment of a PDUFA target action date is an important milestone that puts Tadalafil OSF one step closer to potential approval,” said Dan Barber, Vice President of MonoSol Rx. “Based on the success of our pivotal pharmacokinetic study in 2016 and our status as the first film alternative to tadalafil tablets to file for FDA approval, we believe that our product has significant potential and is well-positioned to compete in the multi-billion dollar erectile dysfunction market. Through our engagement with ESC Advisors, we are continuing to explore partnership opportunities for Tadalafil OSF and look forward to advancing this process as we move closer to our PDUFA date.”
Tadalafil is a PDE5 inhibitor currently marketed in tablet form for the treatment of erectile dysfunction and benign prostatic hyperplasia (BPH) under the brand name Cialis®, and for treatment of pulmonary arterial hypertension under the brand name Adcirca®. Tadalafil OSF will be offered in single pack doses and is expected to have several Orange Book listed patents upon approval.
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, convenience, and compliance of pharmaceutical products. MonoSol Rx's leadership in film drug technology is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com.
Contact MonoSol Rx Jessica Patel [email protected] The Ruth Group Lee Roth [email protected] (646) 536-7012
